Because elraglusib activated immune cells and increased tumor cell PD-L1 expression, we sought to evaluate the potential for elraglusib to increase the efficacy of ICB and utilized a syngeneic murine colon carcinoma BALB/c murine model using a MSS cell line CT-26 (Figure 4A). Here, CD274 is linked to neoplasm.